Illumina, Inc. vs IAC/Interactivecorp — how do they compare? Illumina, Inc. trades at $265 (market cap $40.43B), while IAC/Interactivecorp trades at $40.94 (market cap $3.02B). The key difference: Illumina, Inc. is far larger — about 13.4× IAC/Interactivecorp's market cap, and Illumina, Inc. is trading nearer its 52-week high, IAC/Interactivecorp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and IAC/Interactivecorp for 79 Days on average.
| ILMN | PPLI | |
|---|---|---|
Market Cap | $40.43B | $3.02B |
Volume | 2,948,626 | 932,191 |
Sector | Health | Media |
52-Week High | $293.69 | $47.62 |
52-Week Low | $91.00 | $31.52 |
Typical Hold Time | 83 Days | 79 Days |
Enterprise Value | $41.79B | $3.51B |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $264.40, down 3.34% on the day but up significantly year-to-date with strong technical momentum. The stock shows bullish moving average signals and trades near pivot point resistance at $268. Fundamentally, the company has delivered three consecutive quarterly earnings beats and returned to profitability in 2025 with $850 million net income after previous losses. Recent catalysts include S&P 500 inclusion effective September 21, 2026, and growing AI integration in genomics applications.
The outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI-driven biological data expansion, while risks involve China market headwinds and elevated valuation multiples. Earnings growth and S&P 500 inclusion provide near-term catalysts, but the stock trades at premium valuations with P/E of 49.96 requiring sustained execution.
PPLI trades at $40.93, down 0.87% on the day, with strong analyst support (71% buy ratings) amid MGM acquisition speculation. The stock shows bullish technical momentum with recent earnings volatility, including a significant Q2 2026 beat. Fundamentals reveal mixed performance with negative 2025 net income but improving 2026 projections, while valuation metrics appear attractive with P/E of 6.87 and P/B of 0.59.
The outlook remains positive due to potential MGM acquisition interest and improving 2026 profitability projections, though risks include inconsistent earnings history and negative cash flow trends. Institutional sentiment is bullish with no sell ratings, supporting near-term upside potential if acquisition talks materialize.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →